Sign In
Buy FBRX
$76.98
+0.450 (+0.588%)
At Close: Jul 30, 2026
Forte Biosciences, Inc. Announces 2025 Results and Provides Update
04:01pm, Tuesday, 31'st Mar 2026
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
04:01pm, Tuesday, 17'th Mar 2026
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclon
Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules
04:01pm, Wednesday, 04'th Mar 2026
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclon
Forte Biosciences (FBRX) Upgraded to Buy: Here's What You Should Know
01:01pm, Wednesday, 25'th Feb 2026
Forte Biosciences (FBRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Forte Biosciences, Inc. to Present at Upcoming Investor Meetings
04:01pm, Monday, 09'th Feb 2026
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced
Investors Purchase Large Volume of Forte Biosciences Call Options (NASDAQ:FBRX)
01:42am, Thursday, 05'th Feb 2026
Forte Biosciences, Inc. (NASDAQ: FBRX - Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Stock investors bought 30,205 call options on the company. This is
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
04:01pm, Monday, 22'nd Dec 2025
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclon
Forte Biosciences, Inc. (NASDAQ:FBRX) Given Average Rating of “Moderate Buy” by Brokerages
03:30am, Saturday, 20'th Dec 2025
Forte Biosciences, Inc. (NASDAQ: FBRX - Get Free Report) has earned a consensus rating of "Moderate Buy" from the five research firms that are presently covering the firm, MarketBeat reports. One inve
Federated Hermes Inc. Buys New Shares in Forte Biosciences, Inc. $FBRX
04:21am, Thursday, 11'th Dec 2025
Federated Hermes Inc. purchased a new position in shares of Forte Biosciences, Inc. (NASDAQ: FBRX) in the second quarter, according to its most recent filing with the SEC. The firm purchased 1,072,233
Forte Biosciences Target of Unusually High Options Trading (NASDAQ:FBRX)
02:12am, Thursday, 27'th Nov 2025
Forte Biosciences, Inc. (NASDAQ: FBRX - Get Free Report) was the recipient of some unusual options trading on Wednesday. Stock traders purchased 30,205 call options on the company. This represents an
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
04:01pm, Monday, 24'th Nov 2025
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclon
Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update
09:00am, Friday, 14'th Nov 2025
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced
Forte Biosciences, Inc. $FBRX Stake Boosted by AlphaQuest LLC
03:59am, Monday, 03'rd Nov 2025
AlphaQuest LLC grew its stake in shares of Forte Biosciences, Inc. (NASDAQ: FBRX) by 300.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission.
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
04:01pm, Friday, 03'rd Oct 2025
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced
Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium
09:00am, Monday, 15'th Sep 2025
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, announced additi
